Chinese Developers Showcase Potentially Differentiated Weight Loss Assets At ADA

Including First-In-Class ActRIIA Antibody

 
• By Xu Hu
  
Scientists (miniature) are gathering at a conference hall for a meeting.
This year’s ADA indicated that muscle-preserving drugs developed by Chinese firms for weight management are mostly in preclinical stage currently. (Shutterstock/AI-generated)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from R&D

More from Therapy Areas